Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-α agents

Clinical and Experimental Rheumatology

Volumn 20, Issue 5 SUPPL. 27, 2002, Pages

  Fleishmann, R M ^a  

^a St Paul University Hospital   (United States)

Author keywords

Anakinra; Biological response modifiers; Etanercept; Infliximab

Indexed keywords

ANTIBIOTIC AGENT; ANTIRHEUMATIC AGENT; CORTICOSTEROID; ETANERCEPT; GOLD DERIVATIVE; INFLIXIMAB; ISOXAZOLE DERIVATIVE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DEMYELINATING DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; INFECTION RISK; INJECTION SITE; LIVER INJURY; LUNG INJURY; MEDICAL PRACTICE; MYCOSIS; OPPORTUNISTIC INFECTION; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; RISK ASSESSMENT; SKIN MANIFESTATION; TUBERCULOSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL RESPONSE MODIFIERS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-1; RECEPTORS, TUMOR NECROSIS FACTOR; SIALOGLYCOPROTEINS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036400157     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. HARRIS ED JR: Rheumatoid arthritis: Pathophysiology and implications for therapy. N Engl J Med 1990; 322: 1277-89.
2. PINCUS T: Long-term outcomes in rheumatoid arthritis. Br J Rheumatol 1995; 34: 59-73.
3. GABRIEL SE: The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001; 27: 269-81.
4. MIKULS TR, SAAG KG: Co morbidity in rheumatoid arthritis. Rheum Dis Clin North Am 2001; 27: 283-303.
5. PINCUS T, CALLAHAN LF, FUCHS HA, LARSEN A, KAYE J: Quantitative analysis of hand radiographs in rheumatoid arthritis: time course of radiographic changes, relation to joint examination measures, and comparison of differing scoring methods. J Rheumatol 1995; 22: 1983-9.
6. CASH JM, KLIPPEL JH: Second-line drug therapy for rheumatoid arthritis. N Engl J Med 1994; 330: 1368-75.
7. BENSEN WG, BENSEN W, ADACHI JD: Back to the future: The pyramids of rheumatoid arthritis. J Rheumatol 1997; 24: 1023-7.
8. FRIES JF, WILLIAMS CA, MORFELD D, SIBLEY J: Reduction in long-term disability in patients with rheumatoid arthritis by disease modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 1996; 39: 616-22.
9. PINCUS T, O'DELL JR, KREMER JM: Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: A preventative strategy. Ann Intern Med 1999; 131: 768-74.
10. JACKSON CG, WILLIAMS HJ: Disease-modifying antirheumatic drugs. Using their clinical pharmacological effects as a guide to their selection. Drugs 1998; 56: 337-44.
11. KREMER JM, ALARCON GS, WEINBLATT ME et al.: Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: A multicenter study with literature review. Arthritis Rheum 1997; 40: 1829-837.
12. SCHIFF MH, WHELTON A: Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis. Semin Arthritis Rheum 2000; 30: 196-208.
13. BRESNIHAN B, ALVARO-GRACIA JM, COBBY M et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196-204.
14. COHEN S, HURD E, CUSH JJ et al.: Treatment of interleukin-1 receptor antagonist in combination with methotrexate (MTX) in rheumatoid arthritis (RA) patients. Arthritis Rheum 1999; 42: S273 (abstr.).
15. JIANG Y, GENANT HK, WATT I, et al.: A multi-center, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000; 43: 1001-9.
16. MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-7.
17. MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al.: Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial. Ann Intern Med 1999; 130: 478-86.
18. BATHON JM, MARTIN RW, FLEISCHMANN RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93.
19. LIPSKY PE, VAN DER HEIJDE DM, ST CLAIR EW et al. and the ANTI-TUMOR NECROSIS FACTOR TRIAL IN RHEUMATOID ARTHRITIS WITH CONCOMITANT THERAPY STUDY GROUP: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594-602.
20. WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor FC fusion protein in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999: 340: 253-9.
21. PINCUS T, STEIN CM: Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: Some explanations and suggestions for future studies. Clin Exp Rheumatol 1997; 12: s27
22. BROOKS P (Ed.): Disease-modifying anti-rheumatic drugs. In: Primer on the Rheumatic Diseases. 11th ed., Atlanta, Georgia, Arthritis Foundation, 1997.
23. GORDON DA, KLINKHOFF AV: Gold and penicillamine. In RUDDY (Ed.): Kelley's Text-book of Rheumatology, 6th ed., St Louis, MO. W.B. Saunders Company, 2001.
24. TAFFET SL, DAS KM: Sulfasalazine: Adverse effects and desensitization. Dig Dis Sci 1983; 28: 833-42.
25. PINCUS T, MARCUM SB, CALLAHAN LF: Long term drug therapy for RA in seven rheumatology private practices. J Rheumatol 1992; 19: 1885-94.
26. WOLFE F: Epidemiology of drug treatment failure in RA. Clin Rheumatol 1995: 9: 619-632.
27. FELSON DT, ANDERSON JJ, MEENAN RE: Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum 1992; 35: 1117-25.
28. GISPEN JG, ALARCON GS, JOHNSON JJ, ACTON RT, BARGER BO, KOOPMAN WJ: Toxicity to methotrexate in RA. J Rheumatol 1987; 14: 74-9.
29. SANDOVAL DM, ALARCON GS, MORGAN SL: Adverse events in methotrexate-treated rheumatoid arthritis patients. Br J Rheumatol 1995; 34: 49-56.
30. STRAND V, COHEN S, SCHIFF M et al.: Treatment of active rheumatoid arthritis with flunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159: 2542-50.
31. WEINBLATT ME, KREMER JM, COBLYN JS et al.: Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42: 1322-8.
32. KREMER JM, CALDWELL JR, CANNON GW et al.: The combination of leflunomide (LEF) and methotrexate (MTX) in patients with active rheumatoid arthritis (RA) who are failing on MTX treatment alone: A double-blind placebo (PLC) controlled study. Arthritis Rheum 2000: 43 (Suppl): S224 (Abstract 948).
33. BRESNIHAN B, ALVARO-GRACIA JM, COBBY M et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196-204.
34. COHEN S, HURD E, CUSH J et al.: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist (IL-1Ra) in combination with methotrexate. Arthritis Rheum 2002: 46: 614-24.
35. COHEN SB, MORELAND LW, CUSH JJ et al.: Anakinra (recombinant interleukin-1 receptor antagonist): A large placebo-controlled efficacy trial of anakinra in patients with erosive rheumatoid arthritis disease (late-breaking abstract). American College of Rheumatology, 65th Annual Meeting, November 11-15, 2001, San Francisco, Ca, USA.
36. FLEISCHMANN R, TESSER J, SCHECHTMAN J et al.: A safety trial of anakinra: recombinant interleukin-1 receptor antagonist (IL-1Ra), in a large, placebo controlled heterogeneous population of patients with rheumatoid arthritis. Arthritis Rheum 2001; 44 (Suppl.) (Abstract No. 190).
37. FLEISCHMANN R, SCHECHTMAN J, BENNETT R et al.: A large, international, multi-center placebo-controlled trial of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHUIL-1ra) in patients with rheumatoid arthritis. Arthritis Rheum (submitted).
38. SCHIFF M, et al.: Arthritis Rheum 2001; 44 (Suppl.): S79.
39. FDA ARTHRITIS ADVISORY COMMITTEE RESOURCE PAGE: Available at http://www.fda.gov/ ohrms/dockets/ac/01/slides/3779s1.htm.
40. DORAN MF, CROWSON CS, O'FALLON WM, GABRIEL SE: Infections in rheumatoid arthritis. Arthritis Rheum 2000; 43: S268.
41. FLEISCHMANN RM, IQBAL I, NANDESHWAR P, QUICENO A: Safety and efficacy of disease modifying anti-reheumatic agents: Focus on the benefits and risks of Etanercept. Drug Safety 2002; 25: 173-197.
42. MOHAN N, EDWARDS ET, CUPPS TR et al.: Demyelination diagnosed during etanercept (TNF receptor fusion protein) therapy. Arthritis Rheum 2000; 43 (Suppl.): S228 (Abstract 970).
43. Etanercept. FDA approved Product Information Sheet.
44. FOOD AND DRUG ADMINISTRATION: Adverse Event Reporting System. Rockville, MD, National Press Office (data on file).
45. LIPSKY PE, VAN DER HEIDJE D, ST. CLAIR W et al.: Infliximab and Methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594-602
46. KEANE J, GERSHON S, WISE R, et al.: Tuberculosis associated with infliximab, a tumor necrosis factor α neutralizing agent? N Engl J Med 2001; 345: 1098-104.
47. CHOY EH, PANAYI GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907-16.